Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Apr;68(4):1525-1528.
doi: 10.1007/s10620-022-07733-z. Epub 2022 Oct 31.

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients

Affiliations

The Frequency of Germline BRCA and Non-BRCA HR-Gene-Variants in a Cohort of Pancreatic Cancer Patients

M Baz et al. Dig Dis Sci. 2023 Apr.

Abstract

Germline DNA alterations affecting homologous recombination pathway genes have been associated with pancreatic cancer (PC) risk. BRCA2 is the most studied gene and affects the management of PC patients and their families. Even though recent reports have suggested a similar role of germline ATM pathogenic variants (PV) in familial PC, there is still a disagreement between experts on how it could affect patient management given the lack of proper PC risk estimates. We retrospectively analyzed the germline data of 257 PC patients among whom nearly 50% were sporadic cases. We showed similar frequencies of BRCA2 (4.9%) and ATM (4.4%) PV or likely pathogenic variants, which were not related to familial history. Based on our findings and that of the literature, we suggest including ATM gene among the panel of genes analyzed in PC patients pending the publication of prospective studies.

Keywords: Germline DNA; Hereditary cancer; Homologous recombination pathway; Next generation sequencing; Pancreatic cancer.

PubMed Disclaimer

References

    1. Klein AP. Genetic susceptibility to pancreatic cancer. Mol Carcinog. 2012;51:14–24. - DOI - PubMed - PMC
    1. Zhen DB, Rabe KG, Gallinger S, Syngal S, Schwartz AG, Goggins MG et al. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study. Genet Med Off J Am Coll Med Genet. 2015;17:569–577.
    1. Goggins M, Schutte M, Lu J, Moskaluk CA, Weinstein CL, Petersen GM et al. Germline BRCA2 gene mutations in patients with apparently sporadic pancreatic carcinomas. Cancer Res. 1996;56:5360–5364. - PubMed
    1. Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ et al. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. N Engl J Med. 2019;381:317–327. - DOI - PubMed - PMC
    1. Hu Y, Guo M. Synthetic lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer. Cancer Sci. 2020;111:3111–3121. - DOI - PubMed - PMC

LinkOut - more resources